BWX Technologies (BWXT): what it does, how it makes money, and why it is no uranium stock

The standard $BWXT story is a nuclear renaissance stock: when uranium and small modular reactors are bid, BWX Technologies goes up, and when the theme cools, it comes down with the miners. That is the half that explains the chart. It does not explain the company.

BWX Technologies is the sole supplier of nuclear reactors to the United States Navy, a cost-plus defence contractor with an $8.4B backlog at 2026-06-30, up 40% in a year, and a 2026 revenue guide of about $3.8B. Its tightest correlations in the QA universe are Comfort Systems ($FIX, 0.60) and Quanta Services ($PWR, 0.59), two construction and electrical contractors, before any uranium name. So the business is a defence franchise with a growing commercial nuclear arm, and the stock trades partly like infrastructure and partly like a nuclear story. This piece walks through what BWXT does, how it makes money, where it sits in the nuclear theme, and the gap between a raised guide and a stock near its low of the year. Figures are as of 2026-10-30 unless noted.

Why it matters now

BWXT closed at $130.70 on 2026-10-30, about 45% under its $238.42 closing high of April 2026, down 3.1% over one month, 24.2% over three months and 38.9% over one year. The 52-week low of $123.05 sits about 6% below the close. The drawdown came after a quarter in which the company raised its full-year guidance and reported a backlog up 40%. Q3 2026 results are expected on 2026-11-02 after the US close: the first print since the stock reached these levels.

What does BWX Technologies do?

BWX Technologies, headquartered in Lynchburg, Virginia, and listed on the NYSE as BWXT, works in two segments.

Government Operations is the core. BWXT is the sole supplier of naval nuclear propulsion reactors and their fuel for the Virginia-class and Columbia-class submarines and the Ford-class aircraft carriers. The same segment runs work for the Department of Energy and the National Nuclear Security Administration, from uranium processing to nuclear materials. Q2 2026 revenue in the segment was $601.3M, up 2% year on year, with operating income down 3%. This is the business that does not shop around: one customer, multi-year programmes, cost-plus contracts.

Commercial Operations builds components and fuel for civilian reactors and services the operating fleet. It is the smaller segment and the one that is growing: Q2 2026 revenue was $302.5M, up 72%, helped by acquisitions. Kinectrics, a Canadian reactor services company, was bought on 2025-05-20 for CAD 782.7M; Precision Components Group, a maker of heavy-walled and heat-transfer components for commercial nuclear, closed on 2026-07-01. BWXT Advanced Technologies, inside this side of the company, carries the small modular reactor and microreactor work that ties BWXT to the SMR theme.

The company is also narrowing its scope. On 2026-07-31 it agreed to sell its medical isotope business (BWXT Medical plus the Kinectrics isotope activities) to Nordic Capital for up to $800M, keeping a minority interest, to focus on defence and commercial nuclear.

How BWXT makes money

Through long contracts, booked years before they turn into revenue.

Naval reactors on cost-plus terms. The Navy pays for the work plus a fee. That makes revenue predictable and margins stable, and it also caps how much margin can expand: a good year does not reprice the contract. Government Operations' 2% growth in Q2 is what a mature franchise looks like.

A backlog that is growing faster than revenue. Company figures from the Q2 2026 10-Q: remaining performance obligations of $8.4B at 2026-06-30, up 40% in a year, with the government backlog alone up 53%. About 55% of it is expected to convert into revenue by the end of 2027. The backlog dipped from the first quarter, which the company puts down to the timing of large multi-year awards.

Commercial nuclear, bought as much as built. The 72% jump in Commercial Operations revenue leans on Kinectrics and now Precision Components. The organic question is whether the civilian reactor fleet's life extensions, uprates and new builds keep feeding that segment once the acquisitions lap.

The 2026 guide, raised with the Q2 release on 2026-08-03: revenue of about $3.8B, adjusted EBITDA of $662M to $672M, non-GAAP earnings per share of $4.70 to $4.80, and free cash flow of $345M to $360M. These are guides, not results. Trailing revenue stands at $3.51B with a 10.1% profit margin (QA data, 2026-10-30).

Against that, the balance sheet carries $2.02B of long-term debt at 2026-06-30, after the acquisitions.

Where it sits in the nuclear theme

BWXT sits in QA's Nuclear / SMR bubble as a primary member (weight 0.85) and maps onto the Nuclear theme. Its role is the reactor-manufacturing leg: the company that builds reactors today, for a customer that has bought them for decades.

Place it by position in the chain. Miners and developers like Cameco ($CCJ), Denison ($DNN), Uranium Energy ($UEC), Energy Fuels ($UUUU) and NexGen ($NXE) produce the uranium. Enrichers like Centrus ($LEU) turn it into fuel. Reactor developers like Oklo ($OKLO), NuScale ($SMR) and NANO Nuclear ($NNE) design machines that do not yet run. BWXT is the one name in the group that already builds and fuels reactors at industrial scale, and gets paid for it every quarter.

The correlation table shows the market only half-files it as nuclear. BWXT's tightest correlations in the QA universe (as of 2026-10-30) are Comfort Systems (0.60) and Quanta Services (0.59), then Cameco (0.58), Centrus (0.57) and Oklo (0.55). Part defence contractor, part infrastructure builder, part nuclear story. $BWXT does not trade like a uranium miner, which cuts both ways: it is less exposed to the spot price, and less helped when uranium rips.

The numbers

At the midpoint of the EPS guide, $4.75, the close works out to about 28 times this year's guided earnings, our arithmetic on a guide. That multiple was higher in April; what changed between then and now is the price, not the guide, which went up.

The bull case

• A monopoly customer that does not leave. Sole supplier of naval reactors and fuel for three shipbuilding programmes, on multi-year, cost-plus contracts.
• Backlog up 40%, guide raised. $8.4B of remaining performance obligations at 2026-06-30, about 55% of it expected to convert by the end of 2027, and a 2026 guide raised in August.
• Commercial nuclear as the growth engine. Commercial Operations revenue up 72% in Q2, with Kinectrics and Precision Components adding services and components for the operating fleet and new builds.
• Focus. The medical isotope sale, up to $800M, trims a non-core line and funds the defence and commercial nuclear core.
• Cash generation. Free cash flow guided at $345M to $360M for 2026, on a company worth about $12B.

The bear case

• The core barely grows. Government Operations revenue up 2% and operating income down 3% in Q2. Cost-plus contracts keep margins stable; they do not expand them.
• Growth bought, not organic. Much of the 72% commercial jump comes from acquisitions. The comparison gets harder once they lap.
• Valuation still carries a premium. About 28 times guided 2026 earnings (our arithmetic) and 33.9 times trailing earnings for a company whose core grows in low single digits.
• Leverage. $2.02B of long-term debt at 2026-06-30 after two acquisitions.
• The tape. The stock sits about 45% under its April high and within about 6% of its 52-week low; it has fallen while the fundamentals improved, so the fundamentals are not what is driving it.

How to access

BWX Technologies trades on the NYSE as BWXT. To trade it from a US-retail account alongside the rest of the nuclear names, see /stack/ibkr.

QA's holdings data lists BWXT as a 6.21% position in the VanEck Uranium and Nuclear ETF ($NLR) as of 2026-10-30, so an NLR owner already carries a meaningful BWXT weight. Note that NLR, unlike the pure uranium miner funds, holds reactor builders and utilities alongside the miners, which is exactly the part of the theme BWXT belongs to.

The full teardown video is on /stocks/bwxt. The desk's full read in one document is the BWXT Teardown Dossier, included in /pro, along with bubble-correlation shifts and rule-based alerts on $BWXT.

What to watch

• Q3 2026 results, expected 2026-11-02 after the US close. The backlog figure against $8.4B, Government Operations growth against 2%, and whether the 2026 guide holds or moves again.
• The medical business sale. Closing and the use of the proceeds, up to $800M.
• Commercial organic growth. How much of the Commercial Operations line grows once Kinectrics and Precision Components are in both periods.
• Naval awards. The timing of large multi-year contracts, which the company says explains the quarter-to-quarter dips in backlog.
• Observable reference levels. The 52-week range runs from $123.05 to $241.82; QA's auto-computed 0.786 retracement of that range sits at $148.47, above the 2026-10-30 close. These are observable reference levels, not trade levels or targets.
• Bubble-level shift. If BWXT starts tracking Cameco and the uranium pack more tightly than Comfort Systems and Quanta, the market has started trading it as a nuclear stock rather than a contractor. The structural read would change with it.

Live data on this ticker: /stocks/bwxt. Price, peer correlations, levels and the desk's teardown video.

Bubble context: /bubbles/nuclear-smr. The cluster this name belongs to and how it's moving.

QuantAbundance is educational research. Nothing here is investment advice. See /disclosures.